Multiple Sclerosis Trial, Recruiting NCT07230015 Sponsor: Medipol University Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT07230015
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Multiple Sclerosis (MS), confirmed using a specific recognised diagnostic method called the McDonald Criteria
  • People whose MS is the relapsing-remitting type (where symptoms flare up and then partially or fully recover)
  • People whose MS disability level is rated as mild, scoring between 0 and 3 on a scale called the PDDS (confirm with trial site for exact scoring details)
  • People aged between 18 and 45 years old
  • People who have mild difficulties with memory or thinking
  • People who have mild to moderate difficulties with balance
  • People who experience dizziness, vertigo, or unstable vision related to their MS
  • People whose first language is Arabic, as clear communication in Arabic is required for the tasks involved
  • People who are physically able to participate in the two types of treatment used in the trial: mental movement practice (motor imagery) and balance/dizziness rehabilitation exercises

Who may not be able to join:

  • People who have another neurological condition in addition to MS, or whose MS is the progressive type (rather than relapsing-remitting)
  • People whose dizziness or balance problems are caused by a non-MS condition, such as BPPV or Meniere's disease, as this could interfere with the treatment being studied
  • People with severe psychiatric conditions such as schizophrenia or bipolar disorder
  • People with severe balance problems
  • People experiencing severe fatigue
  • People with unstable or serious medical conditions, such as heart or lung disease, active infections, severely uncontrolled diabetes, or severe vision problems
  • People with severe difficulties with memory or thinking
  • People who are pregnant
  • People with advanced physical disability, such as those who use a wheelchair or are unable to stand
  • People who are currently taking medications that suppress or reduce the vestibular (balance and dizziness) system (confirm specific medications with the trial site)
  • People who do not speak Arabic as their first language

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Merve Yılmaz Menek, Assoc. Prof, Assoc. Prof. Merve Yılmaz Menek

Phone: +201040131964

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Medipol University
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
30 May 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Change in Cognitive Function (Montreal Cognitive Assessment [MoCA] Score); Change in Balance Berg Balance Scale \[ABBS] Score); Change in Vestibular Function (Dynamic Visual Acuity [DVA] Test); Change in Vestibular Function (Head Impulse Test [HIT]); Change in Cognitive Function (Brief International Cognitive Assessment for MS \[BICAMS] Composite Score; Change in balance (Timed Up and Go [TUG] Time); Change in Disability Status (Patient-Determined Disease Steps \[PDDS] Score)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov